Document is current
Any future updates will be listed below
-
Authors
Huso, Vienna L. https://orcid.org/0000-0003-2345-2299
Niu, Shuangshuang https://orcid.org/0009-0008-0973-2183
Catipovic, Marco A. https://orcid.org/0000-0001-6766-829X
Saba, James A. https://orcid.org/0000-0003-3453-8151
Denk, Timo https://orcid.org/0000-0002-0761-3294
Park, Eugene https://orcid.org/0000-0002-2617-7571
Cheng, Jingdong https://orcid.org/0000-0003-4442-377X
Berninghausen, Otto https://orcid.org/0000-0002-9255-0522
Becker, Thomas https://orcid.org/0000-0001-8458-2738
Green, Rachel https://orcid.org/0000-0001-9337-2003
Beckmann, Roland https://orcid.org/0000-0003-4291-3898
- License Information
-
More Information
Article History
Received: 1 July 2025
Accepted: 17 October 2025
First Online: 19 November 2025
Competing interests
: R.G. is a member of the scientific advisory board of Alltrna, Initial Therapeutics and Arrakis Pharmaceuticals, and consulted for Bristol Myers Squibb (Celgene) and Monta Rosa Therapeutics. All other authors declare no competing interests.
